Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy
$267m Deal Expands Biotech’s Research
Executive Summary
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
You may also be interested in...
Eli Lilly To Explore MiNA's Small Activating RNA Technology
Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.
Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.